title: Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
abstract: High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.
authors.affiliation: Institut d'hématologie de Basse Normandie, Centre Hospitalier Universiatire, Faculté de médecine, Université de Basse-Normandie, Caen, France.|Microenvironnement Cellulaire et Pathologies, Normandie University, Caen, France.
authors.forename: G
authors.initials: G
authors.lastname: Damaj
authors.affiliation: Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
authors.forename: J
authors.initials: J
authors.lastname: Cornillon
authors.affiliation: Hématologie et Thérapie Cellulaire, CHU de Bordeaux, Pessac, France.
authors.forename: K
authors.initials: K
authors.lastname: Bouabdallah
authors.affiliation: Hématologie, CHU de Grenoble, Grenoble, France.
authors.forename: R
authors.initials: R
authors.lastname: Gressin
authors.affiliation: Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
authors.forename: S
authors.initials: S
authors.lastname: Vigouroux
authors.affiliation: Hématologie, CHU de Nantes, Nantes, France.
authors.forename: T
authors.initials: T
authors.lastname: Gastinne
authors.affiliation: Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: F
authors.initials: F
authors.lastname: Ranchon
authors.affiliation: Hématologie, Hospices Civils de Lyon, Lyon, France.
authors.forename: H
authors.initials: H
authors.lastname: Ghésquières
authors.affiliation: Hématologie, Hospices Civils de Lyon, Lyon, France.
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.affiliation: Maladies du sang, CHRU de Lille, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: Hématologie et Thérapie Cellulaire, CHU de Tours, Tours, France.
authors.forename: E
authors.initials: E
authors.lastname: Gyan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D064592:Autografts; D002330:Carmustine / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine